795 results on '"Bouhnik, Y."'
Search Results
2. P943 Real world Effectiveness and safety of tofacitinib in patients with Ulcerative Colitis: 6 months follow-up of the French TOFAST study
3. P900 A PROOF-OF-CONCEPT, PLACEBO-RANDOMIZED CONTROLLED TRIAL TARGETING ADHERENT AND INVASIVE ESCHERICHIA COLI (AIEC) WITH ANTIBIOTICS IN CROHN’S DISEASE: the TEOREM TRIAL
4. P884 Patient satisfaction and experience after a switch to an adalimumab biosimilar with high concentration and citrate-free: results from a multicentric prospective real-life study
5. P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial
6. P903 Persistence, efficacy and tolerance of subcutaneous Infliximab after switch from intravenous infliximab in IBD patients in remission: one-year results from a multicenter prospective cohort
7. DOP23 The role of histology for the prediction of clinical relapse in Crohn’s Disease: A substudy of the STORI cohort
8. Impact de la prise alimentaire sur l’efficacité d’un traitement par téduglutide chez des patients atteints du syndrome de grêle court
9. Impact Of Food Intake On The Efficacy Of Teduglutide Treatment In Adult Patients With Short Bowel Syndrome
10. Malnutrition Is Common After Weaning Off Parenteral Nutrition In Patients With Short Bowel Syndrome
11. OP14 Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIO
12. P450 Real life Effectiveness and safety of an induction treatment with tofacitinib in patients with Ulcerative Colitis: First results of the French TOFAST cohort
13. P443 Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort Study
14. P404 Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remission
15. P529 Year-two follow-up results of an observational study conducted in Crohn’s disease and ulcerative colitis patients treated with infliximab biosimilar CT-P13 in a real-life setting
16. Practical implementation of faecal transplantation
17. Long‐term efficacy and safety of ustekinumab in 122 refractory Crohnʼs disease patients: a multicentre experience
18. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab
19. Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort
20. DOP047 Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn’s disease: pharmacokinetic–pharmacodynamic analysis of TAILORIX
21. Serum calprotectin as a biomarker for Crohn's disease
22. Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study
23. Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
24. P608 New anti-migration extractible metal stents for Crohnʼs disease strictures: a nationwide GETAID-SFED cohort study
25. P522 A multicenter study to validate Magnetic Resonance Enterography against histological assessments of stenotic disease in patients with Crohnʼs disease
26. P420 Anti-TNF for post-operative prevention in Crohnʼs disease: the detection of anti-drug antibodies at time of surgery is associated with an increased risk of endoscopic recurrence
27. P142 Postoperative course of laparoscopic subtotal colectomy is not affected by preoperative medical treatment in patients with acute colitis complicating inflammatory bowel disease
28. P051 Use of digital technology to boost patient recruitment in inflammatory bowel disease clinical trials
29. DOP027 Long-term efficacy and safety of ustekinumab in refractory Crohnʼs disease patients: a multicenter retrospective experience
30. DOP025 Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAID
31. Intestinal transplantation: Indications and prospects
32. Transplantation intestinale : indications et perspectives
33. Déterminants du sevrage de nutrition parentérale dans une cohorte de patients atteints du syndrome de grêle court suivis dans un centre expert de NPAD
34. DOP36 Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter study
35. P343 Changing the coUrse of cRohn’s disease with an Early use of adalimumab: The CURE study from the GETAID
36. OP01 Withdrawal of infliximab or anti-metabolite therapy in Crohn’s Disease patients in sustained remission on combination therapy: A randomized unblinded controlled trial (SPARE)
37. P350 Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study
38. PERFUSE : étude de cohorte prospective/rétrospective non-interventionnelle de patients en rhumatologie naïfs d’Adalimumab ou en transition recevant le biosimilaire SB5 d’Adalimumab ; analyse de l’expérience patient
39. Impact of teduglutide, a GLP-2 agonist, on inflammatory bowel disease-associated short bowel syndrome: a tertiary single-center study
40. PERFUSE : étude de cohorte prospective/retrospective non-interventionnelle de patients naïfs d’infliximab ou en transition, recevant le biosimilaire SB2 d’infliximab : analyse à 12 mois
41. Structural robustness of the gut mucosal microbiota is associated with Crohnʼs disease remission after surgery
42. Fistula Plug in Fistulising Ano-Perineal Crohn’s Disease: a Randomised Controlled Trial
43. Editorial: what can be done when infliximab stops working in ulcerative colitis? Authorsʼ reply
44. The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab
45. Chronic intestinal pseudo-obstruction.
46. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX ® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis
47. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study
48. Irritable bowel syndrome is more frequent in patients hospitalized for ischaemic colitis: results of a case-control study
49. An aggressive management of acute mesenteric ischemia is associated with satisfactory long-term survival and functional outcomes: F04
50. POS0614 PERFUSE: A FRENCH PROSPECTIVE/RETROSPECTIVE NONINTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; 12-MONTH ANALYSIS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.